GE HealthCare reports third quarter 2026 financial results
GE HealthCare delivered Q3 2026 revenue of $5.5 billion, up 7.2%, with organic growth of 6.2% and growth across all segments. Diluted EPS rose 39.1% to $1.36 and Adjusted EPS grew 25.1% to $1.34, with Adjusted EBIT margin up 180 bps to 16.6%. The company raised FY26 guidance, lifting Adjusted EPS to $4.95-$5.05 from $4.80-$5.00 and free cash flow to $1.6B+. Capital deployment included a 14% dividend increase to $0.04 per share, Q3 free cash flow of $793 million, and a previously announced $945 million cash acquisition of SOFIE Biosciences expected to close in the first half of 2027.
Key figures
- Eps
- 1.36
- Revenue
- 5513000000
- Guidance
- FY26: organic revenue growth ~4.0% (from 3.0-4.0%); Adjusted EBIT margin 15.5-15.7% (from 15.4-15.7%); Adjusted EPS $4.95-$5.05 (from $4.80-$5.00); FCF $1.6B+ (from ~$1.6B)
- Revenue Yoy
- 7.2%
- Fcf
- 793000000
- Backlog
- 23700000000
- Net income
- 615000000
- Adjusted eps
- 1.34
- Book to bill
- 1.03
- Adjusted ebit
- 913000000
- Dividend increase
- 14%
- Net income margin
- 11.1%
- Dividend per share
- 0.04
- Operating cash flow
- 907000000
- Adjusted ebit margin
- 16.6%
- Organic orders growth
- 4.0%
- Organic revenue growth
- 6.2%
- Sofie acquisition price
- 945000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.